+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts

  • PDF Icon

    Report

  • 270 Pages
  • January 2024
  • Region: Global
  • Roots Analysis
  • ID: 4858623

Pharmaceutical Giants Expand Capabilities: WuXi AppTec and Ensoma Lead Acquisitions in Genome Editing Industry

The global genome editing market size for technologies is estimated to be worth USD 3.5 billion in 2023 and is expected to grow at CAGR of 12.6% during the forecast period (2023-2035). Genome editing or gene editing is a genetic engineering technique that enables the modification (insertion, deletion or replacement) of a single gene or a set of genes within the genome of an organism. Over the years, the need for genome editing at the desired site in the genome has resulted in the exploration of various genome editing tools that are being developed by gene editing companies; these include zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and CRISPR technology. These gene editing tools have been extensively used as corrective strategies to treat the clinical conditions which develop as a result of genetic abnormalities, such as sickle cell disease, Parkinson’s disease, hearing loss, peripheral artery disease, spinal muscular atrophy, autoimmune diseases, and other genetic disorders.

Amidst the current initiatives to develop targeted gene edited therapies, gene therapy has emerged as a promising option with over 300 candidates in the clinical trials (as of 2023). It is worth highlighting that prophylaxis treatment is another segment of the gene editing applications that has garnered significant attention in the gene editing market. However, the development of gene edited drug products involves a heavy investment for drug discovery, development, and manufacturing in the gene research industry. Further, in order to ensure the efficiency, precision and safe delivery of these drugs, the pharmaceutical companies have been relying novel genome editing technologies, being developed by genome editing companies. This will eventually aid the drug developers to improve the clinical outcome of the therapeutics by achieving the desired genetic manipulation. Given the ongoing pace of innovation in this field, including encouraging results in clinical trials and accelerated drug approvals, the genome editing market is likely to witness significant market growth during the forecast period.

Key Market Insights

The report features an extensive study of the current market landscape, market size and future opportunities associated with the genome editing market (technologies), during the given forecast period. Further, the genome editing market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the genome editing market analysis are briefly discussed below.

Genome Editing Market: Current Market Landscape

The genome editing market landscape is concentrated with the presence of over 110 genome editing companies (very large, large, mid-sized and small companies). Of these, 57% of the companies were established post-2016, indicating significant start-up activity in the genome editing industry. Examples of companies (established in 2022 and 2023, in alphabetical order) include Akribion Genomics, CorriXR Therapeutics, Couragene, GENETAGUS, GrittGene Therapeutics, Nvelop Therapeutics, Primera Therapeutics and SE Therapeutics.

Moreover, some of the stakeholders engaged in genome editing market also offer gene editing services in order to optimize the use of their resources and augment their revenue generation opportunities. In Europe, Horizon Discovery (also known as Revvity) emerged as the only genetic engineering company whose business model operates via in-house development of gene edited therapies, licensing of its Pin-point™ base editing platform and through genome editing service capabilities.

Market Segmentation - CRISPR/Cas9 are the Most Sought Genome Editing Tools

Of all the genome editing tools, CRISPR technology, specifically, CRISPR-Cas9 has emerged as the leading genetic engineering technique developed by the stakeholders in the gene editing market. Recently, the domain has witnessed a paradigm shift from conventional CRISPR technology to base editing and prime editing techniques. These novel tools are aimed to improve the long-term safety and efficiency of gene delivery. In this market report, the analyst has captured all the genome editing tools (including CRISPR technology) developed by genome editing companies that are relevant to drug discovery, regenerative medicine and diagnostic applications.

Market Segmentation - North America to Hold the Largest Market Share

Over the past few years, there has been a steady increase in the genome editing companies offering various gene editing technologies. Of these, majority of the technology developers are based in North America. It is worth noting that Intellia Therapeutics, Mammoth Biosciences and Metagenomi (arranged in alphabetical order) are the mid-sized companies based in North America that operate as base editing companies.

Genome Editing Market Trends: Technology Licensing Deals are Driving the Overall Partnership Activity

Several stakeholders have been forging alliances with other industry / non-industry players in the genome editing market for different purposes, including technology licensing, research and development, product licensing and product development. It is worth highlighting that, since 2018, over 250 strategic partnerships have been inked by the technology developers in the genome engineering market. Up lately, the pharmaceutical companies have been engaged in the acquisition of other market players engaged in the genome editing industry in order to expand their capabilities and build a comprehensive pipeline. In March 2023, WuXi AppTec acquired OXGENE and enhanced its capabilities for the development of cell and gene therapies. Earlier, in February 2023, Ensoma acquired Twelve Bio, a gene editing company working in area of the CRISPR medicines. As more drug developers license genome editing technology for evaluation, the market growth is expected to witness favorable market growth during the forecast period.

Top Gene Editing Companies Offering Genome Editing Technologies

Examples of top market players that are engaged in offering genome editing technologies (which have also been profiled in this market report; in alphabetical order) Arcturus Therapeutics, Beam Therapeutics, Caribou Biosciences, Century Therapeutics, CRISPR Therapeutics, Editas Medicine, Graphite Bio, Intellia Therapeutics, Prime Medicine and Vor Biopharma. This market report includes an easily searchable excel database of all the genome editing companies worldwide that offer gene editing tools.

Recent Developments Driving the Market Growth of Genome Editing Market

Driven by numerous developmental breakthroughs and results of studies demonstrating the vast potential of gene therapy and cell therapy in the treatment of various diseases, gene editing tools have garnered considerable attention of various market players engaged in the healthcare industry. Several developments have taken place in the field of genome editing, over the past few years. Some of these recent initiatives have been mentioned below. These developments, even if they took place post the release of the market report, substantiate the overall market trends that the analyst has been outlined in the analyses.

  • In October 2023, Intellia Therapeutics announced that the European Medicines Agency (EMA) has granted priority medicine (PRIME) designation to NTLA-2002, an in vivo CRISPR based gene therapy for the treatment of hereditary angioedema.
  • In August 2023, Prime Medicine announced a strategic collaboration with Maxcyte for the development of next-generation gene therapies.
  • In June 2023, CRISPR Therapeutics and Vertex Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) has accepted the Biologics License Applications (BLA) of exa-cel, an ex vivo CRSIPR based gene edited therapy for the treatment of sickle cell disease and transfusion-dependent β-thalassemia.
  • In June 2023, Editas Medicine raised an amount of USD 117.1 million in a secondary offering. It is worth noting that its pipeline candidate EDIT-301 is in early-stage clinical trials for the treatment of sickle cell disease and transfusion-dependent β-thalassemia.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined below:

  • Base Year: 2022
  • Forecast Period: 2023-2035
  • Market Size 2023: $3.5 billion
  • CAGR: 12.6%
  • Type of Gene Editing Technique
    • CRISPR-Cas System
    • TALENs
    • Meganucleases
    • ZFNs
    • Other Techniques
  • Type of Therapy
    • Cell Therapies
    • Gene Therapies
    • Other Therapies
  • Gene Editing Approach
    • Gene Knock-Out Approaches
    • Gene Knock- In Approaches
  • Gene Delivery Method
    • Ex-Vivo Delivery Methods
    • In-Vivo Delivery Methods
    • Gene Delivery Modality
    • Viral Vectors
    • Non-Viral Vectors
  • Application Area
    • Drug Discovery and Development
    • Diagnostics
  • Type of End User
    • Pharmaceutical and Biotechnology Companies
    • Academic and Research Institutes
  • Key Geographical Regions
    • North America
    • Europe
    • Asia-Pacific
  • Payment Method Employed
    • Upfront Payments
    • Milestone Payments
  • Key Companies Profiled
    • Arcturus Therapeutics
    • Avectas
    • Beam Therapeutics
    • Bio-Sourcing
    • Caribou Biosciences
    • Century Therapeutics
    • CRISPR Therapeutics
    • EdiGene
    • Editas Medicine
    • Flash Therapeutics
    • Fortgen
    • G+FLAS Life Sciences
    • Graphite Bio
    • Intellia Therapeutics
    • Ntrans Technologies
    • OXGENE
    • Prime Medicine
    • Revvity (formerly known as Horizon Discovery)
    • TargetGene Biotechnologies
    • Vor Biopharma
    • ZeClinics
  • Excel Data Packs (Complimentary)
    • Technology Landscape Analysis
    • Technology Competitiveness Analysis
    • Partnerships and Collaborations Analysis
    • Patent Analysis
    • Funding and Investment Analysis
    • Market Forecast and Opportunity Analysis
  • Customization Scope: 15% Free Customization Option (equivalent to 5 analysts’ working days)

The genome editing market research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market, across different geographies. Amongst other elements, the report includes:

  • A preface providing an introduction to the full report, Genome Editing Market: Focus on Technology, 2023-2035.
  • An outline of the systematic research methodology adopted to conduct the study on genome editing market (technologies), providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of the findings.
  • An overview of economic factors that impact the overall genome editing market (technologies), including historical trends, currency fluctuation, foreign exchange impact, recession and inflation measurement.
  • An executive summary of the insights captured during the research. It offers a high-level view on the current state of technologies in genome editing industry and its likely evolution in the mid to long term.
  • A general overview of genome editing, including a brief discussion on the evolution of this concept over the years. It also includes information on the various genome editing technologies and the application of genome editing in various industries like biotechnology, pharmaceutical and agriculture. Further, it highlights the various emerging genome editing technologies.
  • A detailed assessment of the current technology landscape of technologies for genome editing based on several relevant parameters, such as type of gene editing technique (CRISPR-Cas system, meganucleases, TALENs, ZFNs and other techniques), gene editing approach (gene knock-in and gene knock-out), type of gene delivery method (in-vivo and ex-vivo), type of gene delivery modality (cells, viral vectors, non- viral vectors and other modalities), highest phase of drug development supported (discovery, preclinical, clinical and commercial), therapeutic area (oncological disorders, genetic disorders, neurological disorders, hematological disorders, immunological disorders, metabolic disorders, ophthalmological disorders, infectious diseases, cardiovascular disorders, hepatic disorders, muscle-related disorders, autoimmune disorders, pulmonary disorders and other disorders) and application area (drug discovery, regenerative medicine, plant gene editing, and diagnostics). In addition, the chapter features information on various technology developers, along with analysis based on multiple parameters, such as year of establishment, company size, location of headquarters, operational model and most active players (in terms of number of technologies developed).
  • An insightful competitiveness analysis of genome editing technologies based on developer strength (in terms of the experience of the developer) and technology strength (in terms of type of gene editing technique, gene editing approach, in-silico (CADD) analysis, type of gene delivery method, type of gene delivery modality, highest phase of development supported and application area).
  • Elaborate profiles of the prominent genome editing companies (shortlisted based on a proprietary criterion) developing genome editing technologies. Each profile features a brief overview of the company, details related to its financial information, technology portfolio, recent developments and an informed future outlook. Further, the chapter also includes profiles of other leading players developing genome editing technologies.
  • A detailed analysis of the partnerships inked between stakeholders in genome editing market, since 2018, covering technology licensing agreements, research and development agreements, technology integration agreements, mergers and acquisitions, product development agreements and other relevant agreements.
  • An in-depth analysis of various patents that have been filed / granted by the technology developers related to genome editing, since 2018, taking into consideration parameters, such as publication year, geographical region, CPC symbols and leading players (in terms of number of patents filled / granted). In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis, highlighting the leading patents (in terms of number of citations).
  • A detailed analysis of funding and investments raised by genome editing technology developers, based on relevant parameters such as year of funding, type of funding, amount invested, regional distribution, most active players (in terms of number of funding instances and amount raised) and most active investors (in terms of number of funding instances).
  • An in-depth analysis of the factors that can impact the growth of genome editing market (technologies). It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.

One of the key objectives of this market report was to estimate the current genome editing market size, opportunity and the future growth potential of the genome editing market (technologies), over the forecast period. the analyst has provided informed estimates on the likely evolution of the market for the forecast period, 2023-2035. the year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of gene editing technique (CRISPR-Cas System, TALENs, meganucleases, ZFNs and other techniques), type of therapy (cell therapies, gene therapies and other therapies), gene editing approach (gene knock-out approaches and gene knock-in approaches), gene delivery method (ex-vivo and in-vivo), gene delivery modality (viral vectors and non-viral vectors), application area (drug discovery and development, and diagnostics), type of end user (pharmaceutical and biotechnology companies, and academic and research institutes), key geographical regions (North America, Europe and Asia-Pacific) and payment method employed (upfront payments and milestone payments). In order to account for future uncertainties associated with some of the key parameters and to add robustness to the model, the analyst has provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market growth.

The opinions and insights presented in the report were influenced by discussions held with stakeholders in this industry. The report features detailed transcripts of interviews held with various industry stakeholders.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past
Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Introduction to Genome Editing
5.2.1. Evolution of Genome Editing
5.2.2. Genome Editing Technologies
5.2.2.1. CRISPR - Cas System
5.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)
5.2.2.3. Zinc Finger Nucleases (ZFNs)
5.2.2.4. Meganucleases / Homing Endonucleases
5.3. Applications of Genome Editing Technologies
5.4. Other Emerging Technologies
5.5. Concluding Remarks
6. TECHNOLOGY LANDSCAPE
6.1. Chapter Overview
6.2. Genome Editing: Technology Landscape
6.2.1. Analysis by Type of Gene Editing Technique
6.2.2. Analysis by Gene Editing Approach
6.2.3. Analysis by Type of Gene Delivery Method
6.2.4. Analysis by Type of Gene Delivery Modality
6.2.5. Analysis by Highest Phase of Drug Development Supported
6.2.6. Analysis by Therapeutic Area
6.2.7. Analysis by Application Area
6.3. Genome Editing: Technology Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.3.4. Analysis by Operational Model
6.3.5. Most Active Players: Distribution by Number of Technologies
7. TECHNOLOGY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Technology Competitiveness Analysis
7.4.1. Genome Editing Technologies Offered by Players based in North America
7.4.2. Genome Editing Technologies Offered by Players based in Europe
7.4.3. Genome Editing Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Latin America
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Arcturus Therapeutics
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Technology Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. Beam Therapeutics
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Technology Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. Caribou Biosciences
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Technology Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Century Therapeutics
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Technology Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. CRISPR Therapeutics
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Technology Portfolio
8.6.4. Recent Developments and Future Outlook
8.7. Editas Medicine
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Technology Portfolio
8.7.4. Recent Developments and Future Outlook
8.8. Graphite Bio
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Recent Developments and Future Outlook
8.9. Intellia Therapeutics
8.9.1. Company Overview
8.9.2. Financial Information
8.9.3. Technology Portfolio
8.9.4. Recent Developments and Future Outlook
8.10. Prime Medicine
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Recent Developments and Future Outlook
8.11. Vor Biopharma
8.11.1. Company Overview
8.11.2. Technology Portfolio
8.11.3. Recent Developments and Future Outlook
8.12. Other Leading Players
8.12.1. Avectas
8.12.2. Bio-Sourcing
8.12.3. Edigene
8.12.4. Flash Therapeutics
8.12.5. Fortgen
8.12.6. G+FLAS Life Sciences
8.12.7. Ntrans Technologies
8.12.8. OXGENE
8.12.9. Revvity (formerly known as Horizon Discovery)
8.12.10. TargetGene Biotechnologies
8.12.11. ZeClinics
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Genome Editing Technologies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Analysis by Geography
9.3.7.1. Local and International Agreements
9.3.7.2. Intercontinental and Intracontinental Agreements
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Genome Editing Domain: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Type of Patent and Publication Year
10.3.3. Analysis by Geography
10.3.4. Analysis by CPC Symbols
10.3.5. Leading Industry Players: Analysis by Number of Patents
10.4. Genome Editing Domain: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.2. Analysis by Leading Industry Players
10.5. Patent Valuation Analysis
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Genome Editing Domain: Funding and Investment Analysis
11.3.1. Analysis by Year of Investment
11.3.1.1. Cumulative Year-wise Trend of Funding Instances
11.3.1.2. Cumulative Year-wise Trend of Amount Invested
11.3.2. Analysis by Type of Funding
11.3.2.1. Analysis of Funding Instances
11.3.2.2. Analysis of Amount Invested
11.3.3. Analysis by Year and Type of Funding
11.3.4. Analysis by Geography
11.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
11.3.6. Leading Investors: Analysis by Number of Funding Instances
12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
12.1. Chapter Overview
12.2. Market Drivers
12.3. Market Restraints
12.4. Market Opportunities
12.5. Market Challenges
12.6. Conclusion
13. GENOME EDITING TECHNOLOGIES MARKET
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Genome Editing Technologies Market, Forecasted Estimates (2023-2035)
13.3.1. Scenario Analysis
13.4. Key Market Segmentations
13.5. Dynamic Dashboard
14. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. CRISPR-Cas System: Forecasted Estimates (2023-2035)
14.4. TALENs: Forecasted Estimates (2023-2035)
14.5. Meganucleases: Forecasted Estimates (2023-2035)
14.6. ZFNs: Forecasted Estimates (2023-2035)
14.7. Other Techniques: Forecasted Estimates (2023-2035)
14.8. Data Triangulation
14.8.1. Insights from Primary Research
14.8.2. Insights from Secondary Research
14.8.3. Insights from In-house Repository
15. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Cell Therapies: Forecasted Estimates (2023-2035)
15.4. Gene Therapies: Forecasted Estimates (2023-2035)
15.5. Other Therapies: Forecasted Estimates (2023-2035)
15.6. Data Triangulation
15.6.1. Insights from Primary Research
15.6.2. Insights from Secondary Research
15.6.3. Insights from In-house Repository
16. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Gene Knock-Out Approaches: Forecasted Estimates (2023-2035)
16.4. Gene Knock-In Approaches: Forecasted Estimates (2023-2035)
16.5. Data Triangulation
16.5.1. Insights from Primary Research
16.5.2. Insights from Secondary Research
16.5.3. Insights from In-house Repository
17. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Ex-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
17.4. In-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
17.5. Data Triangulation
17.5.1. Insights from Primary Research
17.5.2. Insights from Secondary Research
17.5.3. Insights from In-house Repository
18. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Viral Vectors: Forecasted Estimates (2023-2035)
18.4. Non-Viral Vectors: Forecasted Estimates (2023-2035)
18.5. Data Triangulation
18.5.1. Insights from Primary Research
18.5.2. Insights from Secondary Research
18.5.3. Insights from In-house Repository
19. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Drug Discovery and Development: Forecasted Estimates (2023-2035)
19.4. Diagnostics: Forecasted Estimates (2023-2035)
19.5. Data Triangulation
19.5.1. Insights from Primary Research
19.5.2. Insights from Secondary Research
19.5.3. Insights from In-house Repository
20. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Pharmaceutical and Biotechnology Companies: Forecasted Estimates (2023-2035)
20.4. Academic and Research Institutes: Forecasted Estimates (2023-2035)
20.5. Data Triangulation
20.5.1. Insights from Primary Research
20.5.2. Insights from Secondary Research
20.5.3. Insights from In-house Repository
21. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Forecasted Estimates (2023-2035)
21.4. Europe: Forecasted Estimates (2023-2035)
21.5. Asia-Pacific: Forecasted Estimates (2023-2035)
21.6. Data Triangulation
21.6.1. Insights from Primary Research
21.6.2. Insights from Secondary Research
21.6.3. Insights from In-house Repository
22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Milestone Payments: Forecasted Estimates (2023-2035)
22.4. Upfront Payments: Forecasted Estimates (2023-2035)
22.5. Data Triangulation
22.5.1. Insights from Primary Research
22.5.2. Insights from Secondary Research
22.5.3. Insights from In-house Repository
23. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS
23.1. Chapter Overview
23.2. Leading Industry Players
24. CONCLUSION25. EXECUTIVE INSIGHTS26. APPENDIX 1: TABULATED DATA27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 4.1 Executive Summary: Technology Landscape
Figure 4.2 Executive Summary: Partnerships and Collaborations
Figure 4.3 Executive Summary: Patent Analysis
Figure 4.4 Executive Summary: Funding and Investment Analysis
Figure 4.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Genome Editing: Milestones Achieved in Gene Editing Domain
Figure 5.2 Types of Genome Editing Technologies
Figure 5.3 CRISPR / Cas System: Mechanism of Action
Figure 5.4 TALENs: Mechanism of Action
Figure 5.5 ZFNs: Mechanism of Action
Figure 5.6 Meganucleases / Homing Endonucleases: Mechanism of Action
Figure 5.7 Applications of Genome Editing Technologies
Figure 6.1 Genome Editing Technologies: Distribution by Type of Gene Editing Technique
Figure 6.2 Genome Editing Technologies: Distribution by Gene Editing Approach
Figure 6.3 Genome Editing Technologies: Distribution by Type of Gene Delivery Method
Figure 6.4 Genome Editing Technologies: Distribution by Type of Gene Delivery Modality
Figure 6.5 Genome Editing Technologies: Distribution by Highest Phase of Drug Development Supported
Figure 6.6 Genome Editing Technologies: Distribution by Therapeutic Area
Figure 6.7 Genome Editing Technologies: Distribution by Application Area
Figure 6.8 Genome Editing Technology Developers: Distribution by Year of Establishment
Figure 6.9 Genome Editing Technology Developers: Distribution by Company Size
Figure 6.10 Genome Editing Technology Developers: Distribution by Location of Headquarters
Figure 6.11 Genome Editing Technology Developers: Distribution by Company Size and Location of Headquarters
Figure 6.12 Genome Editing Technology Developers: Distribution by Operational Model
Figure 6.13 Genome Editing Technology Developers: Distribution by Product Centric Model
Figure 6.14 Genome Editing Technology Developers: Distribution by Technology Centric Model
Figure 6.15 Most Active Players: Distribution by Number of Technologies
Figure 7.1 Technology Competitiveness Analysis: Genome Editing Technologies Offered by players based in North America
Figure 7.2 Technology Competitiveness Analysis: Genome Editing Technologies Offered by players based in Europe
Figure 7.3 Technology Competitiveness Analysis: Genome Editing Technologies Offered by players based in Asia-pacific, Middle East and North Africa, and Latin America
Figure 8.1 Arcturus Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Figure 8.2 Beam Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Figure 8.3 Caribou Biosciences: Annual Revenues, FY 2020-H1 FY 2023 (USD Million)
Figure 8.4 Century Therapeutics: Annual Revenues, H1 FY 2022-H1 FY 2023 (USD Million)
Figure 8.5 CRISPR Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Figure 8.6 Editas Medicine: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Figure 8.7 Intellia Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Technology Licensing / Integration Agreements: Distribution by Secondary Purpose of Partnership
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.6 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Figure 9.7 Most Active Players: Analysis by Number of Partnerships
Figure 9.8 Partnerships and Collaborations: Distribution by Region
Figure 9. Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 9.10 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2023
Figure 10.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 10.4 Patent Analysis: Distribution by Geography
Figure 10.5 Patent Analysis: Distribution by CPC Symbols
Figure 10.6 Leading Industry Players: Distribution by Number of Patents
Figure 10.7 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 10.8 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 10.9 Patent Analysis: Distribution by Patent Age
Figure 10.10 Patent Analysis: Valuation Analysis
Figure 11.1 Funding and Investments: Cumulative Year-wise Trend of Funding Instances, 2018-2023
Figure 11.2 Funding and Investments: Cumulative Year-wise Trend of Amount Invested, 2018-2023 (USD Million)
Figure 11.3 Funding and Investments: Distribution of Funding Instances by Type of Funding
Figure 11.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 11.5 Funding and Investments: Distribution of Funding Instances by Year and Type of Funding
Figure 11.6 Funding and Investments: Distribution of Funding Instances by Geography
Figure 11.7 Most Active Players: Distribution by Amount Invested and Number of Funding Instances
Figure 11.8 Leading Investors: Distribution by Number of Funding Instances
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
Figure 13.3 Global Genome Editing Technologies Market, Forecasted Estimates (2023-2035), Base Scenario (USD Billion)
Figure 13.4 Global Genome Editing Technologies Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Billion)
Figure 13.5 Global Genome Editing Technologies Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Billion)
Figure 14.1 Global Genome Editing Technologies Market: Distribution by Gene Editing Technique, 2023 and 2035 (USD Billion)
Figure 14.2 Genome Editing Technologies Market for CRISPR-Cas System, Forecasted Estimates (2023-2035) (USD Billion)
Figure 14.3 Genome Editing Technologies Market for TALENs, Forecasted Estimates (2023-2035) (USD Billion)
Figure 14.4 Genome Editing Technologies Market for Meganucleases, Forecasted Estimates (2023-2035) (USD Billion)
Figure 14.5 Genome Editing Technologies Market for ZFNs, Forecasted Estimates (2023-2035) (USD Billion)
Figure 14.6 Genome Editing Technologies Market for Other Techniques, Forecasted Estimates (2023-2035) (USD Billion)
Figure 15.1 Global Genome Editing Technologies Market: Distribution by Type of Therapy, 2023 and 2035 (USD Billion)
Figure 15.2 Genome Editing Technologies Market for Cell Therapies, Forecasted Estimates (2023-2035) (USD Billion)
Figure 15.3 Genome Editing Technologies Market for Gene Therapies, Forecasted Estimates (2023-2035) (USD Billion)
Figure 15.4 Genome Editing Technologies Market for Other Therapies, Forecasted Estimates (2023-2035) (USD Billion)
Figure 16.1 Global Genome Editing Technologies Market: Distribution by Gene Editing Approach, 2023 and 2035 (USD Billion)
Figure 16.2 Genome Editing Technologies Market for Knock-Out Approaches, Forecasted Estimates (2023-2035) (USD Billion)
Figure 16.3 Genome Editing Technologies Market for Knock-In Approaches, Forecasted Estimates (2023-2035) (USD Billion)
Figure 17.1 Global Genome Editing Technologies Market: Distribution by Gene Delivery Method, 2023 and 2035 (USD Billion)
Figure 17.2 Genome Editing Technologies Market for Ex-Vivo Delivery Methods, Forecasted Estimates (2023-2035) (USD Billion)
Figure 17.3 Genome Editing Technologies Market for In-Vivo Delivery Methods, Forecasted Estimates (2023-2035) (USD Billion)
Figure 18.1 Global Genome Editing Technologies Market: Distribution by Gene Editing Modality, 2023 and 2035 (USD Billion)
Figure 18.2 Genome Editing Technologies Market for Viral Vectors, Forecasted Estimates (2023-2035) (USD Billion)
Figure 18.3 Genome Editing Technologies Market for Non-Viral Vectors, Forecasted Estimates (2023-2035) (USD Billion)
Figure 19.1 Global Genome Editing Technologies Market: Distribution by Application Area, 2023 and 2035 (USD Billion)
Figure 19.2 Genome Editing Technologies Market for Drug Discovery and Development, Forecasted Estimates (2023-2035) (USD Billion)
Figure 19.3 Genome Editing Technologies Market for Diagnostics, Forecasted Estimates (2023-2035) (USD Billion)
Figure 20.1 Global Genome Editing Technologies Market: Distribution by Type of End User, 2023 and 2035 (USD Billion)
Figure 20.2 Genome Editing Technologies Market for Pharmaceutical and Biotechnology Companies, Forecasted Estimates (2023-2035) (USD Billion)
Figure 20.3 Genome Editing Technologies Market for Academic and Research Institutes, Forecasted Estimates (2023-2035) (USD Billion)
Figure 21.1 Global Genome Editing Technologies Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Billion)
Figure 21.2 Genome Editing Technologies Market in North America, Forecasted Estimates (2023-2035) (USD Billion)
Figure 21.3 Genome Editing Technologies Market in Europe, Forecasted Estimates (2023-2035) (USD Billion)
Figure 21.4 Genome Editing Technologies Market in Asia-Pacific, Forecasted Estimates (2023-2035) (USD Billion)
Figure 22.1 Global Genome Editing Technologies Market: Distribution by Type of Payment Method Employed, 2023 and 2035 (USD Billion)
Figure 22.2 Genome Editing Technologies Market for Milestone Payments, Forecasted Estimates (2023-2035) (USD Billion)
Figure 22.3 Genome Editing Technologies Market for Upfront Payments, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.1 Concluding Remarks: Overall Technology Landscape
Figure 24.2 Concluding Remarks: Partnerships and Collaborations
Figure 24.3 Concluding Remarks: Patent Analysis
Figure 24.4 Concluding Remarks: Funding and Investment Analysis
Figure 24.5 Concluding Remarks: Market Forecast and Opportunity Analysis
LIST OF TABLES
Table 6.1 Genome Editing Technologies: Information on Type of Gene Editing Technique
Table 6.2 Genome Editing Technologies: Information on Technology Principle (in case of CRISPR-Cas System)
Table 6.3 Genome Editing Technologies: Information on Type of Gene Editing Approach
Table 6.4 Gene Editing Technologies: Information on In-silico (CADD) Analysis
Table 6.5 Genome Editing Technologies: Information on Type of Gene Delivery Method
Table 6.6 Genome Editing Technologies: Information on Type of Gene Delivery Modality
Table 6.7 Genome Editing Technologies: Information on Route of Administration
Table 6.8 Genome Editing Technologies: Information on Highest Phase of Drug Development Supported
Table 6.9 Genome Editing Technologies: Information on Therapeutic Area
Table 6.10 Genome Editing Technologies: Information on Application Area
Table 6.11 Genome Editing Technologies: List of Technology Developers
Table 6.12 Genome Editing Technology Developers: Information on Operational Model
Table 8.1 Genome Editing Technology Developers: List of Companies Profiled
Table 8.2 Arcturus Therapeutics: Company Overview
Table 8.3 Arcturus Therapeutics: Technology Portfolio
Table 8.4 Arcturus Therapeutics: Recent Developments and Future Outlook
Table 8.5 Beam Therapeutics: Company Overview
Table 8.6 Beam Therapeutics: Technology Portfolio
Table 8.7 Beam Therapeutics: Recent Developments and Future Outlook
Table 8.8 Caribou Biosciences: Company Overview
Table 8.9 Caribou Biosciences: Technology Portfolio
Table 8.10 Caribou Biosciences: Recent Developments and Future Outlook
Table 8.11 Century Therapeutics: Company Overview
Table 8.12 Century Therapeutics: Technology Portfolio
Table 8.13 Century Therapeutics: Recent Developments and Future Outlook
Table 8.14 CRISPR Therapeutics: Company Overview
Table 8.15 CRISPR Therapeutics: Technology Portfolio
Table 8.16 CRISPR Therapeutics: Recent Developments and Future Outlook
Table 8.17 Editas Medicine: Company Overview
Table 8.18 Editas Medicine: Technology Portfolio
Table 8.19 Editas Medicine: Recent Developments and Future Outlook
Table 8.20 Graphite Bio: Company Overview
Table 8.21 Graphite Bio: Technology Portfolio
Table 8.22 Graphite Bio: Recent Developments and Future Outlook
Table 8.23 Intellia Therapeutics: Company Overview
Table 8.24 Intellia Therapeutics: Technology Portfolio
Table 8.25 Intellia Therapeutics: Recent Developments and Future Outlook
Table 8.26 Prime Medicine: Company Overview
Table 8.27 Prime Medicine: Technology Portfolio
Table 8.28 Prime Medicine: Recent Developments and Future Outlook
Table 8.29 Vor Biopharma: Company Overview
Table 8.30 Vor Biopharma: Technology Portfolio
Table 8.31 Vor Biopharma: Recent Developments and Future Outlook
Table 8.32 Avectas: Company Overview
Table 8.33 Avectas: Technology Portfolio
Table 8.34 Bio-Sourcing: Company Overview
Table 8.35 Bio-Sourcing: Technology Portfolio
Table 8.36 Edigene: Company Overview
Table 8.37 Edigene: Technology Portfolio
Table 8.38 Flash Therapeutics: Company Overview
Table 8.39 Flash Therapeutics: Technology Portfolio
Table 8.40 Fortgen: Company Overview
Table 8.41 Fortgen: Technology Portfolio
Table 8.42 G+FLAS Life Sciences: Company Overview
Table 8.43 G+FLAS Life Sciences: Technology Portfolio
Table 8.44 Ntrans Technologies: Company Overview
Table 8.45 Ntrans Technologies: Technology Portfolio
Table 8.46 OXGENE: Company Overview
Table 8.47 OXGENE: Technology Portfolio
Table 8.48 Revvity (formerly known as Horizon Discovery): Company Overview
Table 8.49 Revvity (formerly known as Horizon Discovery): Technology Portfolio
Table 8.50 TargetGene Biotechnologies: Company Overview
Table 8.51 TargetGene Biotechnologies: Technology Portfolio
Table 8.52 ZeClinics: Technology Portfolio
Table 8.53 ZeClinics: Technology Portfolio
Table 9.1 Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership, and Type of Partner, 2018-2023
Table 9.2 Technology Licensing / Integration Agreements: Information on Secondary Purpose of Partnership
Table 9.3 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Continent-wise), 2018-2023
Table 10.1 Patent Analysis: List of Top CPC Sections
Table 10.2 Patent Analysis: List of Top CPC Symbols
Table 10.3 Patent Analysis: List of Top CPC Codes
Table 10.4 Patent Analysis: Categorizations based on Weighted Valuation Scores
Table 10.5 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 11.1 Genome Editing Technologies: List of Funding and Investments
Table 13.1 Genome Editing Technologies: Average Upfront Payment and Average Milestone Payment, 2018-2023 (USD Million)
Table 26.1 Genome Editing Technologies: Distribution by Type of Gene Editing Technique
Table 26.2 Genome Editing Technologies: Distribution by Gene Editing Approach
Table 26.3 Genome Editing Technologies: Distribution by Type of Gene Delivery Method
Table 26.4 Genome Editing Technologies: Distribution by Type of Gene Delivery Modality
Table 26.5 Genome Editing Technologies: Distribution by Highest Phase of Drug Development Supported
Table 26.6 Genome Editing Technologies: Distribution by Therapeutic Area
Table 26.7 Genome Editing Technologies: Distribution by Application Area
Table 26.8 Genome Editing Technology Developers: Distribution by Year of Establishment
Table 26.9 Genome Editing Technology Developers: Distribution by Company Size
Table 26.10 Genome Editing Technology Developers: Distribution by Location of Headquarters
Table 26.11 Genome Editing Technology Developers: Distribution by Company Size and Location of Headquarters
Table 26.12 Genome Editing Technology Developers: Distribution by Operational Model
Table 26.13 Genome Editing Technology Developers: Distribution by Product Centric Model
Table 26.14 Genome Editing Technology Developers: Distribution by Technology Centric Model
Table 26.15 Most Active Players: Distribution by Number of Technologies
Table 26.16 Arcturus Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Table 26.17 Beam Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Table 26.18 Caribou Biosciences: Annual Revenues, FY 2020-H1 FY 2023 (USD Million)
Table 26.19 Century Therapeutics: Annual Revenues, H1 FY 2022-H1 FY 2023 (USD Million)
Table 26.20 CRISPR Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Table 26.21 Editas Medicine: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Table 26.22 Intellia Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Table 26.23 Partnerships and Collaborations: Distribution by Type of Partnership
Table 26.24 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 26.25 Technology Licensing / Integration Agreements: Distribution by Secondary Purpose of Partnership
Table 26.26 Partnerships and Collaborations: Distribution by Type of Partner
Table 26.27 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Table 26.28 Most Active Players: Analysis by Number of Partnerships
Table 26.29 Partnerships and Collaborations: Distribution by Region
Table 26.30 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 26.31 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 26.32 Patent Analysis: Distribution by Type of Patent
Table 26.33 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2023
Table 26.34 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 26.35 Patent Analysis: Distribution by Geography
Table 26.36 Patent Analysis: Distribution by CPC Symbols
Table 26.37 Leading Industry Players: Distribution by Number of Patents
Table 26.38 Funding and Investments: Cumulative Year-wise Trend of Funding Instances, 2018-2023
Table 26.39 Funding and Investments: Cumulative Year-wise Trend of Amount Invested, 2018-2023 (USD Million)
Table 26.40 Funding and Investments: Distribution of Funding Instances by Type of Funding
Table 26.41 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Table 26.42 Funding and Investments: Distribution of Funding Instances by Year and Type of Funding
Table 26.43 Funding and Investments: Distribution of Funding Instances by Geography
Table 26.44 Most Active Players: Distribution by Amount Invested and Number of Funding Instances
Table 26.45 Leading Investors: Distribution by Number of Funding Instances
Table 26.46 Global Genome Editing Technologies Market, Forecasted Estimates (2023-2035), Base Scenario (USD Billion)
Table 26.47 Global Genome Editing Technologies Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Billion)
Table 26.48 Global Genome Editing Technologies Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Billion)
Table 26.49 Global Genome Editing Technologies Market: Distribution by Gene Editing Technique, 2023 and 2035 (USD Billion)
Table 26.50 Genome Editing Technologies Market for CRISPR-Cas System, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.51 Genome Editing Technologies Market for TALENs, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.52 Genome Editing Technologies Market for Meganucleases, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.53 Genome Editing Technologies Market for ZFNs, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.54 Genome Editing Technologies Market for Other Techniques, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.55 Global Genome Editing Technologies Market: Distribution by Type of Therapy, 2023 and 2035 (USD Billion)
Table 26.56 Genome Editing Technologies Market for Cell Therapies, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.57 Genome Editing Technologies Market for Gene Therapies, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.58 Genome Editing Technologies Market for Other Therapies, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.59 Global Genome Editing Technologies Market: Distribution by Gene Editing Approach, 2023 and 2035 (USD Billion)
Table 26.60 Genome Editing Technologies Market for Knock-Out Approaches, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.61 Genome Editing Technologies Market for Knock-In Approaches, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.62 Global Genome Editing Technologies Market: Distribution by Gene Delivery Method, 2023 and 2035 (USD Billion)
Table 26.63 Genome Editing Technologies Market for Ex-Vivo Delivery Methods, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.64 Genome Editing Technologies Market for In-Vivo Delivery Methods, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.65 Global Genome Editing Technologies Market: Distribution by Gene Editing Modality, 2023 and 2035 (USD Billion)
Table 26.66 Genome Editing Technologies Market for Viral Vectors, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.67 Genome Editing Technologies Market for Non-Viral Vectors, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.68 Global Genome Editing Technologies Market: Distribution by Application Area, 2023 and 2035 (USD Billion)
Table 26.69 Genome Editing Technologies Market for Drug Discovery and Development, Forecasted

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 2seventy bio
  • 5AM Ventures
  • 683 Capital
  • AbbVie
  • Abcam
  • Acrigen Biosciences
  • Acuitas Therapeutics
  • Affini-T Therapeutics
  • Aju IB Investments
  • Akribion Genomics
  • Aldevron
  • Alexion Pharmaceuticals
  • Alia Therapeutics 
  • Allogene Therapeutics
  • Ally Bridge Group
  • Almirall
  • Altitude Life Science Ventures
  • Altium Capital
  • Amgen Ventures
  • Andreessen Horowitz
  • AnGes
  • Ankarys Therapeutics
  • ANLBIO
  • APEIRON Biologics
  • Apellis Pharmaceuticals
  • Applied Biological Materials
  • Applied StemCell
  • Arbor Biotechnologies
  • ARCH Venture Partners
  • Arctoris
  • Arcturus Therapeutics
  • Arix Bioscience
  • Armistice Capital
  • ArrowMark Partners
  • ArsenalBio
  • Artisan Bio
  • Asahi Kasei Corporate Venture Capital
  • Ascenion
  • Asklepios BioPharmaceutical
  • Astellas Pharma
  • AstraZeneca
  • ATCC
  • ATLATL Innovation Centre
  • Avectas
  • Avoro Capital Advisors
  • Avoro Ventures
  • Axcelead
  • Axxam
  • Bain Capital Life Sciences
  • Bayer
  • Beam Therapeutics 
  • Bill & Melinda Gates Foundation
  • Bio Palette
  • Bio-Sourcing
  • Biocytogen
  • Biogen
  • Bioluminescence Ventures
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Bioneer
  • Blink Therapeutics
  • BlueRock Therapeutics
  • BOP Capital
  • Boston Children's Hospital
  • Boxer Capital
  • BRAIN Biotech
  • BrainXell
  • Branca Bunús
  • BrightPath Biotherapeutics
  • Bristol-Myers Squibb
  • Broad Institute of MIT and Harvard
  • Brookhaven Bio
  • Byers Capital
  • C4U
  • C4X Discovery
  • CaaS Capital
  • Cabaletta Bio
  • California Institute for Regenerative Medicine (CIRM)
  • Canaccord Genuity
  • CANbridge Pharmaceuticals
  • Capsida Biotherapeutics
  • Capstan Therapeutics
  • Caribou Biosciences
  • Cartherics
  • CasCure Therapeutics
  • Casdin Capital
  • Caszyme
  • Catalent
  • Catalio Capital Management
  • Catamaran Bio
  • CCRM
  • CD Capital
  • Cellecta
  • Cellectis
  • CellFE
  • Celularity
  • Center for Breakthrough Medicines
  • Central Institute for Experimental Animals (CIEA)
  • Century Therapeutics
  • CF Foundation
  • CHA Biotech
  • CHA Research Institute
  • Charcot-Marie-Tooth Association
  • China Life Healthcare Fund
  • ChristianaCare
  • Cimeio Therapeutics
  • Clairvoyant Ventures
  • CMB International Capital Holdings
  • Cormorant Asset Management
  • CorriXR Therapeutics
  • Cosmo Bio
  • Cota Capital
  • Couragene
  • Cowen Healthcare Investments
  • CPE
  • Creative Biogene
  • CRISP-HR Therapeutics
  • CRISPR Biotech Engineering
  • Crispr Stem & Therapeutics
  • CRISPR Therapeutics
  • Crown Bioscience
  • CSL Seqirus
  • Curamys
  • Curia
  • CyGenica
  • Cystic Fibrosis Foundation
  • Cytosurge
  • Cytovia Therapeutics
  • D1 Capital Partners
  • Daiichi Sankyo
  • Danaher
  • DCI Partners
  • Decheng Capital
  • DefiniGEN
  • Delos Capital
  • Duke University School of Medicine
  • Duke-NUS Medical School
  • Dynamk Capital
  • EcoR1 Capital
  • EdiGene
  • Editas Medicine
  • eGenesis
  • Elaia Partners
  • Eledon Pharmaceuticals
  • Eli Lilly
  • Emendo Biotherapeutics 
  • Emerson Collective
  • Empirica
  • Ennovation Ventures
  • Ensoma
  • EPIQ Capital Group
  • ERS Genomics
  • ETP Ventures
  • Euclidean Capital
  • Eurofins
  • European Innovation Council (EIC)
  • European Investment Bank
  • EV Biologics
  • Evercrisp Biosciences
  • Evotec
  • Excision BioTherapeutics
  • Exothera
  • F-Prime Capital
  • Farallon Capital
  • FASMAC
  • Feldan Therapeutics
  • Flash Therapeutics
  • Foresite Capital
  • Fortgen
  • Fresenius Medical Care Ventures (FMCV)
  • Friedreich’s Ataxia Research Alliance (FARA)
  • FUJIFILM Cellular Dynamics
  • Future Fields
  • G+FLAS Life Sciences
  • GC Cell
  • GEcoll Biomedical
  • GEMoaB
  • GenAhead Bio
  • GeneLancet Biosciences
  • Genentech
  • GENETAGUS
  • Genethon
  • Genexine
  • GenKOre
  • GenNBio
  • genOway
  • GenScript
  • German Center for Neurodegenerative Diseases (DZNE)
  • Gilead Sciences
  • GL Ventures
  • GordonMD Global Investments
  • Graphite Bio
  • GreatPoint Ventures
  • Green Cross LabCell 
  • Green Sands
  • Gritstone Oncology
  • GrittGene Therapeutics
  • GSK Consumer Healthcare
  • Guide Therapeutics (a subsidiary of Beam Therapeutics)
  • Haihe Laboratory of Cell Ecosystem
  • Hamburg Investment and Development Bank
  • Hangzhou Huixin Biotechnology
  • Hansa Biopharma
  • Harvard University
  • Hatteras Investment Partners
  • HBM Healthcare Investments
  • HebeCell
  • Heights Capital
  • Hera Biolabs
  • Hercules Capital
  • Hitachi Ventures
  • Horizon Technology Finance
  • Hunterian Medicine
  • IDG Capital
  • iECURE
  • Illumina
  • Immatics
  • Immunochina
  • In Vivo Biosystems (formerly known as NemaMetrix)
  • Inceptor Bio
  • Incisive Genetics
  • Infinome Biosciences
  • Inhibrx
  • Innovation Agency
  • Innovationsstarter Fonds Hamburg
  • Inscripta
  • Intellia Therapeutics
  • Intima Bioscience
  • Invesco Asset Management
  • Investissement Québec
  • Invus
  • Ionis Pharmaceuticals
  • Iovance Biotherapeutics
  • Irving Investors
  • Israeli Ministry of Health
  • JAFCO
  • Janssen Biotech
  • Japan SLC
  • Jasper Therapeutics
  • Jenthera Therapeutics
  • JS Capital Management
  • JW Therapeutics
  • Karius
  • Kite Pharma
  • Kite Ventures
  • Kiwoom Investment
  • Kleiner Perkins
  • KRYSP-R
  • KSQ Therapeutics
  • Kyverna Therapeutics
  • Lake Bleu Capital
  • Lapam Capital
  • Leaps by Bayer
  • Lepton Pharmaceuticals
  • LG Chem
  • Life Edit Therapeutics
  • LifeSci Venture Partners
  • Lilly Asia Venture
  • LogicBio Therapeutics
  • Longmen Capital
  • Lonza
  • Loyal Valley Capital
  • Lyell Immunopharma
  • LYFE Capital
  • MacHall Group
  • Macrogen
  • Madison Avenue Partners
  • Magenta Therapeutics
  • Makana Therapeutics
  • Mammoth Biosciences
  • Matrix Partners China
  • Maxcyte
  • Mayfield
  • Mayo Clinic
  • Memorial Sloan Kettering Cancer Center
  • Mercia
  • Merck
  • Metagenomi
  • Micro CRISPR 
  • MidCap Financial
  • Mind the Byte
  • Mizuho Securities
  • Modalis Therapeutics
  • Moderna
  • Mogrify
  • Monashee Investment Management
  • Moogene Medi
  • Morningside Ventures
  • Myeloid Therapeutics
  • Myllia Biotechnology (formerly known as Aelian Biotechnology)
  • Mérieux Développement
  • Nanjing Bioheng Biotech
  • National Institutes of Health (NIH)
  • National Science Foundation
  • Nephrogen
  • Neukio Biotherapeutics
  • New England Biolabs
  • New South Wales Government
  • Newpath Partners
  • Newtyn Management
  • Nippon Gene
  • Nkarta
  • Noile-Immune Biotech
  • Novartis
  • Novartis Gene Therapies (formerly known as AveXis)
  • Novo Holdings
  • Novo Nordisk
  • Ntrans Technologies
  • NUVISAN ICB
  • Nvelop Therapeutics
  • Oak HC/FT
  • Octagon Capital
  • ONK Therapeutics
  • Orbital Therapeutics
  • Osage University Partners
  • Otsuka Pharmaceutical
  • Outpace Bio
  • Oxford Finance
  • OXGENE
  • Paladin Capital
  • PanCELLa
  • Pangen Biotech
  • Panmure Gordon
  • Pantherna Therapeutics
  • Parker Institute for Cancer Immunotherapy (PICI)
  • Peking Union Medical College Hospital
  • Peking University Cancer Hospital
  • Pencil Biosciences
  • Perceptive Advisors
  • Pfizer
  • PFM Health Sciences
  • Phen Vista
  • Pluristyx
  • Polaris Partners
  • Polyplus-transfection
  • Precision BioSciences
  • Prevail Therapeutics
  • Prime Medicine
  • Primera Therapeutics
  • Primordial Genetics
  • ProBioGen
  • Promega
  • Prorenata Biotech
  • PROVIREX Genome Editing Therapies
  • Qihan Biotech
  • QUIDDITAS Therapeutics
  • RA Capital Management
  • Recipharm
  • ReCode Therapeutics
  • Recombinetics
  • Red Tree Venture Capital
  • Redmile Group
  • Reforgene Medicine
  • Rege Nephro
  • Regeneron
  • Resilience
  • Revvity (formerly known as Horizon Discovery) 
  • Rewrite Therapeutics
  • Ridgeback Capital Investments
  • Rock Springs Capital
  • RTW Investments
  • Rutgers University
  • Samsara BioCapital
  • Sana Biotechnology
  • Sandhill Therapeutics
  • Sangamo Therapeutics
  • Sanofi
  • Santa Cruz Biotechnology
  • Sanzheng Health Investment
  • Scottish Enterprise
  • Scribe Therapeutics
  • SDIC Venture Capital
  • SE Therapeutics
  • Seamus Mulligan
  • Seattle Children’s Research Institute
  • Sequoia Capital China
  • Sestina Bio
  • Setsuro Tech
  • Shanghai BDgene Technology
  • Shoreline Biosciences
  • Silicon Valley Bank
  • Simcere Pharmaceuticals
  • Singapore Economic Development Board (EDB)
  • SJ Investment Partners
  • SML Genetree
  • Sofinnova Partners
  • Solana Biosciences
  • Songhe Capital
  • SOSV
  • SparingVision
  • Sphere Fluidics
  • Spotlight Therapeutics
  • SpringWorks Therapeutics
  • Starfish Innovations
  • Stellate DNA
  • STIC Ventures
  • Stifel
  • Strongest Hearts Foundation
  • Sumitomo
  • SymBiosis
  • Syngulon
  • Synthego
  • T&R Biofab
  • T-MAXIMUM Biotech
  • Takara Bio
  • Takeda Pharmaceuticals
  • TargetGene Biotechnologies
  • Taros Chemicals
  • TCG Crossover
  • TCR² Therapeutics
  • TechLife Capital
  • Temasek
  • Teneobio
  • The Wells Investment
  • Thermo Fisher Scientific
  • Tiziana Life Sciences
  • Tofflon
  • ToolGen
  • TPG Capital
  • TransCode Therapeutics
  • Transomic Technologies
  • TransViragen
  • Trentino Invest
  • Tsinghua Holdings Capital
  • Twelve Bio (a subsidiary of Ensoma)
  • Twist Bioscience
  • TxCell
  • University of Bern
  • University of California
  • University of California San Francisco
  • University of Edinburg
  • University of Miami
  • University of North Carolina
  • University of Pennsylvania
  • University of Wisconsin-Madison
  • Versant Ventures
  • Vertex Pharmaceuticals
  • Verve Therapeutics
  • Vesigen Therapeutics
  • ViaCyte
  • Vida Ventures
  • Vingroup
  • VirEdit Biosciences
  • Viromer Transfection
  • Virostem Biotechnology
  • viTToria Biotherapeutics
  • VivaZome Therapeutics
  • Vivlion
  • Vor Biopharma
  • Voyager Therapeutics
  • Walking Fish Therapeutics
  • Wellington Management
  • Western Alliance Bank
  • Westlake Village BioPartners
  • WuXi AppTec
  • Yaotang (Shanghai) Biotechnology
  • Yuansheng Venture Capital
  • ZeClinics
  • Zhejiang University

Methodology

 

 

Loading
LOADING...

Table Information